Precision medicine in bronchiectasis
Open Access
- 7 December 2021
- journal article
- review article
- Published by European Respiratory Society (ERS) in Breathe
- Vol. 17 (4) , 210119
Abstract
Bronchiectasis, due to its highly heterogenous nature, requires an individualised approach to therapy. Patients experience symptoms and exacerbations driven by a combination of impaired mucociliary clearance, airway inflammation and airway infection. Treatment of bronchiectasis aims to enhance airway clearance and to address the underlying causes of inflammation and infection susceptibility. Bronchiectasis has multiple causes and so the pathophysiology leading to individual symptoms and exacerbations are different between individuals. Standardised investigations are recommended by international guidelines to identify the underlying causes of bronchiectasis. The process of identifying the underlying biology within an individual is called “endotyping” and is an emerging concept across chronic diseases. Endotypes that have a specific treatment are referred to as “treatable traits” and a treatable traits approach to managing patients with bronchiectasis in a holistic and evidence-based manner is the key to improved outcomes. Bronchiectasis is an area of intense research. Endotyping allows identification of subsets of patients to allow medicines to be tested differently in the future where trials, rather than trying to achieve a “one size fits all” solution, can test efficacy in subsets of patients where the treatment is most likely to be efficacious.Keywords
This publication has 91 references indexed in Scilit:
- The Bronchiectasis Severity Index. An International Derivation and Validation StudyAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasisMolecular Immunology, 2013
- Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota compositionThorax, 2013
- Short- and Long-Term Antibiotic Treatment Reduces Airway and Systemic Inflammation in Non–Cystic Fibrosis BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Pulmonary Nontuberculous Mycobacterial Disease Prevalence and Clinical Features: An Emerging Public Health DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous diseaseThe Lancet, 2008
- Aetiology in adult patients with bronchiectasisRespiratory Medicine, 2007
- Tobramycin Solution for Inhalation Reduces Sputum Pseudomonas aeruginosa Density in BronchiectasisAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Effects of Human Neutrophil Elastase and Pseudomonas aeruginosa Proteinases on Human Respiratory EpitheliumAmerican Journal of Respiratory Cell and Molecular Biology, 1991
- APPROPRIATE DOSE ANTIBIOTICS IN CHRONIC BRONCHIAL SEPSISThe Lancet, 1984